Izabela Dróżdż (Izabela Drozdz, Izabela Dróżdz)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 17

Top Topics

Multiple Myeloma

Patients Undergoing

Top Venues

International journal of molecular sciences

Journal of clinical medicine

Cardiovascular diabetology

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Aleksandra Ryk, Anna Marcinkiewicz, Jędrzej Chrzanowski, Arkadiusz Mariusz Michalak, Izabela Dróżdż, Jacek Burzyński, Michał Krejca, Wojciech Fendler
Cholesin receptor signalling is active in cardiovascular system-associated adipose tissue and correlates with SGLT2i treatment in patients with diabetes. Cardiovascular diabetology 23 (1) (2024)
Damian Mikulski, Kacper Kościelny, Izabela Dróżdż, Grzegorz Mirocha, Mateusz Nowicki, Małgorzata Misiewicz, Ewelina Perdas, Piotr Strzałka, Agnieszka Świątek, Wojciech Fendler
Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. International journal of molecular sciences 25 (8) (2024)
Damian Mikulski, Kacper Kościelny, Izabela Dróżdż, Grzegorz Mirocha, Mateusz Nowicki, Małgorzata Misiewicz, Ewelina Perdas, Piotr Strzałka, Agnieszka Świątek, Wojciech Fendler
Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. International journal of molecular sciences 25 (8) (2024)
Aleksandra Ryk, Anna Marcinkiewicz, Jędrzej Chrzanowski, Arkadiusz Mariusz Michalak, Izabela Dróżdż, Jacek Burzyński, Michał Krejca, Wojciech Fendler
Cholesin receptor signalling is active in cardiovascular system-associated adipose tissue and correlates with SGLT2i treatment in patients with diabetes. Cardiovascular diabetology 23 (1) (2024)
Aleksandra Ryk, Anna Marcinkiewicz, Jędrzej Chrzanowski, Arkadiusz Mariusz Michalak, Izabela Dróżdż, Jacek Burzyński, Michał Krejca, Wojciech Fendler
Cholesin receptor signalling is active in cardiovascular system-associated adipose tissue and correlates with SGLT2i treatment in patients with diabetes. Cardiovascular diabetology 23 (1) (2024)
Damian Mikulski, Kacper Kościelny, Izabela Dróżdż, Grzegorz Mirocha, Mateusz Nowicki, Małgorzata Misiewicz, Ewelina Perdas, Piotr Strzałka, Agnieszka Świątek, Wojciech Fendler
Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. International journal of molecular sciences 25 (8) (2024)
Damian Mikulski, Kacper Kościelny, Izabela Dróżdż, Mateusz Nowicki, Małgorzata Misiewicz, Ewelina Perdas, Piotr Strzałka, Agnieszka Świątek, Wojciech Fendler
High Serum miR-361-3p Predicts Early Postdischarge Infections after Autologous Stem Cell Transplantation. Infection & chemotherapy (2024)
Anna Puła, Pawel Robak, Dariusz Jarych, Damian Mikulski, Małgorzata Misiewicz, Izabela Dróżdż, Wojciech Fendler, Janusz Zbigniew Szemraj, Tadeusz Robak
The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. International journal of molecular sciences 24 (3) (2023)
Sylwia Magdalena Berus, Ariadna B Nowicka, Julia Wieruszewska, Krzysztof Niciński, Aneta A Kowalska, Tomasz R Szymborski, Izabela Dróżdż, Maciej Borowiec, Jacek Waluk, Agnieszka Kamińska
SERS Signature of SARS-CoV-2 in Saliva and Nasopharyngeal Swabs: Towards Perspective COVID-19 Point-of-Care Diagnostics. International journal of molecular sciences 24 (11) (2023)
Anna Puła, Pawel Robak, Dariusz Jarych, Damian Mikulski, Małgorzata Misiewicz, Izabela Dróżdż, Wojciech Fendler, Janusz Zbigniew Szemraj, Tadeusz Robak
The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. International journal of molecular sciences 24 (3) (2023)
Anna Puła, Tadeusz Robak, Izabela Dróżdż, Konrad Stawiski, Aleksander Rycerz, Małgorzata Misiewicz, Pawel Robak
Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens - pilot study. Leukemia & lymphoma (2023)
Anna Puła, Pawel Robak, Dariusz Jarych, Damian Mikulski, Małgorzata Misiewicz, Izabela Dróżdż, Wojciech Fendler, Janusz Zbigniew Szemraj, Tadeusz Robak
The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. International journal of molecular sciences 24 (3) (2023)
Bartłomiej Pawlik, Szymon Grabia, Urszula Smyczynska, Wojciech Fendler, Izabela Dróżdż, Ewa Liszewska, Jacek Jaworski, Katarzyna Kotulska, Sergiusz Jozwiak, Wojciech Mlynarski, Joanna Trelińska
MicroRNA Expression Profile in TSC Cell Lines and the Impact of mTOR Inhibitor. International journal of molecular sciences 23 (22) (2022)
Bartłomiej Pawlik, Urszula Smyczynska, Szymon Grabia, Wojciech Fendler, Izabela Dróżdż, Katarzyna Bąbol-Pokora, Katarzyna Kotulska, Sergiusz Jozwiak, Julita Borkowska, Wojciech Mlynarski, Joanna Trelińska
mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex Is Associated with Specific Changes in microRNA Serum Profile. Journal of clinical medicine 11 (12) (2022)
Igor Aleksander Bednarski, Magdalena Ciążyńska, Karolina Wódz, Izabela Dróżdż, Małgorzata Skibińska, Joanna Narbutt, Aleksandra Lesiak
Hippo Signaling Pathway as a New Potential Target in Non-Melanoma Skin Cancers: A Narrative Review. Life (Basel, Switzerland) 11 (7) (2021)
Paweł Robak, Janusz Zbigniew Szemraj, Damian Mikulski, Izabela Dróżdż, Karolina Juszczak, Dariusz Jarych, Małgorzata Misiewicz, Kacper Kościelny, Wojciech Fendler, Tadeusz Robak
Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. Journal of clinical medicine 10 (21) (2021)
Damian Mikulski, Paweł Robak, Ewelina Perdas, Edyta Węgłowska, Aleksandra Łosiewicz, Izabela Dróżdż, Dariusz Jarych, Małgorzata Misiewicz, Janusz Zbigniew Szemraj, Wojciech Fendler, Tadeusz Robak
Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib. Journal of clinical medicine 11 (1) (2021)